SERA: Sera Prognostics Average Forecast Price

Sera Prognostics generates revenue through the sale of advanced biomarker assays designed to manage the risks of preterm birth. However, the company relies on existing cash reserves due to a negative operating balance and the early stage of product implementation, with the current metric standing at 5.47. This price chart illustrating trading dynamics complements data regarding strategic partnerships with clinics and insurers to optimize prenatal monitoring.

SERA: Sera Prognostics, Inc. Analyst Consensus Forecast 07/04/2022 - 11/11/2026

Analytical breakdowns for Sera Prognostics, Inc. (SERA)

- price and consensus price forecast:

Market Chart seraprognostics.com|SERA - Analyst Consensus Forecast

- market capitalization information:

Market Value Sera Prognostics|SERA - Total Company Value

- shareholders' equity book value data:

Accounting Value of a Share Sera Prognostics|SERA - Book Capitalization|Market Capitalization to Book Value Ratio seraprognostics.com|SERA - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Sera Prognostics|SERA - Long-Term Debt to Capital|Current Liabilities to Capital Sera Prognostics Inc.|SERA - Company Debts|Debts to Book Capitalization Ratio Sera Prognostics|SERA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Sera Prognostics|Immediate Liquidity seraprognostics.com

- earnings and valuation multiples information:

SERA - Net Profit|Net Profit Forecast Sera Prognostics|SERA - Price to Earnings Ratio|Forward P/E Multiple seraprognostics.com|SERA - PEG Multiple|Enterprise Value to EBITDA Ratio Sera Prognostics|SERA - Operating profit before deduction of amortization|Earnings per share for the last four quarters Sera Prognostics|SERA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months seraprognostics.com|SERA - Earnings per share growth in current year|Expected net earnings per share growth next year Sera Prognostics

Fundamental company analysis:seraprognostics.com - SERA

Finished products of Sera Prognostics, Inc.

Sera Prognostics (SERA) is transforming prenatal screening through the synthesis of proteomics and artificial intelligence, a process that necessitates capital-intensive R&D expenditures. The consensus target price aggregates experts' average monetary expectations in real-time, converting scientific potential and market risks into a fundamental benchmark for an objective assessment of the company's fair equity value.

Competitors of Sera Prognostics

Analyst Median Target natera.com|Analyst Consensus Forecast HUMA (Humacyte)